REGISTRY SNAPSHOT: Central Committee on Research Involving Human Subjects (CCMO)

by Staff writer,
Posted on 1/15/2019

Ministry of Health, Welfare and Sport

Ministry of Health, Welfare and Sport. Hague, the Netherlands.

Knowing what countries to submit clinical trial results summaries to is the easy part. What becomes difficult is learning the intricacies and transparency requirements of every clinical trial registry globally, including the Central Committee on Research Involving Human Subjects (CCMO) in the Netherlands. Here is an overview of this registry:

Registry name: Central Committee on Research Involving Human Subjects (CCMO)

Country: The Netherlands

Year established: 1999

Points of interest:

  • The Central Committee on Research Involving Human Subjects (CCMO) was established on April 6, 1999, on the basis of section 14 of the Medical Research Involving Subjects Act (WMO).
  • The National Clinical Trial Office supports the CCMO and 12 accredited medical research ethics committees (MRECs) in reviewing research with a medicinal product.
  • All study results must be submitted via https://www.toetsingonline.nl/
  • The summary of the study results is disclosed in the CCMO register 15 days after it has been added to ToetsingOnline.
  • Lay summaries are not obligatory but are an option for disclosing study results.
  • Sponsors that do not wish to disclose study results in the Netherlands can submit an objection letter to ccmo@ccmo.nl.
  • The CCMO is housed in the Ministry of Health, Welfare and Sport in Hague, the Netherlands.

TrialAssure® Registry can automate the disclosure of clinical trial results in the Netherlands for the CCMO. For questions or a free demo, fill out this form.

Share: